Skip to content

Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality

Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality: A Randomized Controlled Trial Evaluating Efficacy and Safety

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07501975
Enrollment
498
Registered
2026-03-30
Start date
2026-04-01
Completion date
2026-12-31
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy

Brief summary

In recent years, with the continuous advancement of digestive endoscopy techniques, how to improve the adenoma detection rate (ADR) by optimizing endoscopic procedural details has become a research hotspot. Colonic spasm can lead to narrowing of the intestinal lumen, deepening of mucosal folds, and limited field of view, thereby affecting lesion exposure and reducing examination quality. Although traditional intravenous antispasmodic drugs (such as scopolamine) can alleviate intestinal spasms, they may cause side effects such as increased heart rate, blood pressure fluctuations, and other systemic adverse reactions. In contrast, menthol is a natural monoterpene compound derived from peppermint oil. It can inhibit L-type calcium channels on the cell membrane of smooth muscle through local application, thereby reducing intracellular calcium concentration and inducing smooth muscle relaxation. This helps to relieve intestinal spasms and patient discomfort during colonoscopy. On the other hand, simethicone, a commonly used defoaming agent, can reduce surface tension, eliminate foam, and improve mucosal visualization. Theoretically, combining antispasmodic menthol with defoaming simethicone may further optimize the visual field during colonoscopy and increase the ADR through a synergistic "antispasmodic + defoaming" mechanism. Therefore, this study plans to conduct a prospective randomized controlled trial to evaluate the antispasmodic effect, safety, and impact on the ADR of a novel irrigation solution (0.1% menthol combined with simethicone suspension) in colonoscopy, providing evidence-based medical support for optimizing endoscopic procedures.

Interventions

DIAGNOSTIC_TESTEndoscopic irrigation was performed using a novel irrigation solution

Endoscopic irrigation was performed using a novel irrigation solution (0.1% menthol solution combined with simethicone aqueous suspension).

DIAGNOSTIC_TESTIrrigation was performed endoscopically using normal saline.

Irrigation was performed endoscopically using normal saline.

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age between 18 and 75 years, regardless of gender; 2. Scheduled to undergo colonoscopy (for screening, diagnostic, or follow-up purposes); 3. Adequate bowel preparation quality (Boston Bowel Preparation Scale score ≥ 6); 4. Voluntarily signed informed consent and able to cooperate with completing study-related assessments.

Exclusion criteria

1. Allergy to menthol, cyclodextrin, or related substances; 2. History of severe intestinal diseases (such as ulcerative colitis, Crohn's disease, intestinal perforation, intestinal obstruction, intestinal tumors, etc.); 3. Presence of severe dysfunction of vital organs such as the heart, liver, kidneys, or lungs, or coagulation disorders; 4. Pregnant or lactating women; 5. Use of anticholinergic drugs, calcium channel blockers, or other spasmolytic agents within one week prior to the examination; 6. Psychiatric disorders or cognitive impairment that prevent cooperation with the study; 7. History of contraindications to colonoscopy or serious adverse reactions during previous procedures.

Design outcomes

Primary

MeasureTime frameDescription
Adenoma detection rate (ADR).Day 0ADR = (number of patients with at least one adenomatous polyp detected / total number of patients in the group) × 100%. Pathological diagnosis was used as the gold standard.

Secondary

MeasureTime frameDescription
Incidence of intestinal spasmDay 0The percentage of patients with an intestinal spasm score of 2 or 3 out of the total number of patients in the group. Intestinal spasm scoring criteria: Score 1 (Excellent): No spasm; the lumen opening is greater than or equal to two-thirds of the maximum diameter. Score 2 (Moderate): Moderate spasm; the lumen opening is less than two-thirds of the maximum diameter. Score 3 (Poor): Severe spasm; the oral-side lumen cannot be visualized. The maximum diameter is defined as the diameter of the intestinal lumen when fully distended.
Spasm inhibition rateDay 0The percentage of patients whose lumen opening exceeded two-thirds of the maximum diameter within 30 seconds after water injection irrigation, relative to the total number of patients in the group.
Polyp detection rate (PDR)Day 0PDR = (number of patients with at least one polyp detected / total number of patients in the group) × 100%.

Contacts

CONTACTJianning Yao
rjyy@zzu.edu.cn13733183434

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026